Further, the sale of pharmaceutical products overseas at lower prices than in the United States could adversely impact our U.S. pricing strategy and financial condition if the contemplated U.S. federal health care program Most-Favored-Nation pricing proposal is ultimately adopted. As a result of such policy, we may elect not to expand our business to certain foreign countries, which would limit our market opportunity.
All entries for: Lyell Immunopharma
April 8, 2025
Lyell Immunopharma
Layoffs
South San Francisco, CA
51-200 employees
Five months after acquiring the cell therapy company ImmPACT Bio, Lyell Immunopharma has disclosed that it is shutting down the Los Angeles manufacturing facility that was part of the deal and letting go of 73 people at the site. The layoffs are effective June 2, according to a Worker Adjustment and Retraining Notification Act (WARN) notice.
Disease Area: Oncology
Drug Type: Biologic